Peripheral Neuropathy

Neurology
3
Pipeline Programs
5
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

E
EisaiChina - Liaoning
1 program
1
Mecobalamin IV InjectionPhase 41 trial
Active Trials
NCT01192113Completed1,072Est. May 2011
Genentech
GenentechCA - Oceanside
1 program
1
RituxanPhase 21 trial
Active Trials
NCT00006072Unknown
WinSanTor
WinSanTorCA - San Diego
1 program
1
WST-057Phase 21 trial
Active Trials
NCT04005287CompletedEst. Dec 2021
C
CENTOGENEGermany - Rostock
1 program
Biomarker for Metachromatic Leukodystrophy (BioMeta) DiseaseN/A1 trial
Active Trials
NCT01536327Withdrawn0Est. Feb 2021
BlueWind Medical
BlueWind MedicalIsrael - Herzliya
1 program
The Reprieve SystemN/A1 trial
Active Trials
NCT02062398CompletedEst. Dec 2015

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
EisaiMecobalamin IV Injection
WinSanTorWST-057
CENTOGENEBiomarker for Metachromatic Leukodystrophy (BioMeta) Disease
BlueWind MedicalThe Reprieve System

Clinical Trials (5)

Total enrollment: 1,072 patients across 5 trials

NCT01192113EisaiMecobalamin IV Injection

Safety and Efficacy of Mecobalamin Injection in Peripheral Neuropathies Patients (Study JGAZSY091109)

Start: Apr 2010Est. completion: May 20111,072 patients
Phase 4Completed
NCT00006072GenentechRituxan

A Study of Rituxan in the Treatment of Polyneuropathies Associated With Serum IgM Autoantibodies

Phase 2Unknown
NCT04005287WinSanTorWST-057

A 24-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Peripheral Neuropathy

Start: Oct 2019Est. completion: Dec 2021
Phase 2Completed
NCT01536327CENTOGENEBiomarker for Metachromatic Leukodystrophy (BioMeta) Disease

Biomarker for Metachromatic Leukodystrophy (BioMeta) Disease

Start: Aug 2018Est. completion: Feb 20210
N/AWithdrawn
NCT02062398BlueWind MedicalThe Reprieve System

BlueWind Medical Reprieve System for the Treatment of PNP

Start: May 2014Est. completion: Dec 2015
N/ACompleted

Related Jobs in Neurology

Director, Distribution & Services

Xenon Pharmaceuticals
Remote
7h ago

Senior Medical Science Liaison (NYC Tri-State)

Xenon Pharmaceuticals
Remote
7h ago
$208K - $234K/yr

Director of Medical Affairs

CoMind
Miami, FL
7h ago

Director of Finance

CoMind
London, UK
7h ago

Electronics Engineering Manager

CoMind
London, UK
7h ago

Director of Information Technology

Zavation Medical Products
7h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 companies competing in this space

Related Indications

Multiple Sclerosis(274)Schizophrenia(255)Epilepsy(242)Parkinson Disease(171)Alzheimer's Disease(165)Parkinson's Disease(160)Alzheimer Disease(117)Stroke(102)Relapsing-Remitting Multiple Sclerosis(83)Depression(82)